S. Parisi

The Biotransformation and Pharmacokinetics of 14C-Nimesulide in Humans Following a Single Dose Oral Administration

K. Rainsford, A. Hewson, D. Macpherson, 2012 .

Pharmacokinetic and Safety Evaluation of Palonosetron, a 5‐Hydroxytryptamine‐3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects

J. Cyong, Ajit K. Shah, R. Stoltz, 2004, Journal of clinical pharmacology.

Pharmacokinetics, metabolism and excretion of intravenous [l4C]‐palonosetron in healthy human volunteers

A. Macciocchi, Ajit K. Shah, R. Stoltz, 2004, Biopharmaceutics & drug disposition.

Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers

J. Morganroth, K. Flaharty, C. Moresino, 2015, Supportive Care in Cancer.

1156 POSTER High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo

J. Morganroth, M. Thorn, M. Cullen, 2007 .